Positive phase 2 studies on EYP-1901 in AMD, DME offer promise as treatment moves into phase 3 programs
Ramiro Ribeiro, MD, PhD, of EyePoint, spoke with Ophthalmology 360 at AAO 2025 about clinical trial progress and findings related to their investigational therapy, Duravyu, which is being evaluated for wet AMD and DME. Duravyu offers a new target for these conditions.
Ramiro Ribeiro, MD, PhD:
Hi, my name is Ramiro Ribeiro. I’m the Chief Medical Officer at EyePoint, and we are here at AAO 2025 in Orlando.
We just gave updates on our clinical program. Our lead candidate called Duravyu, also known as EYP-1901, has been studied in the indication of wet AMD, DME, and NPDR. Duravyu is a multi-target tyrosine kinase inhibitor that blocks the VEGF receptors, PDGF receptors. This week, we announced our R&D findings, that Duravyu has also an effect on the JAK1 receptor, which is part of the IL-6 pathway. Those results were highlighted at the Eyecelerator meeting and were based on our phase 2 VERONA DME trial. Duravyu has been dosed in over 190 patients across 3 different retinal indications, and our safety profile is excellent. We have shown positive results in the phase 2 studies for DME and wet AMD. In our wet AMD phase 2 study, DAVIO 2, we show that patients that received Duravyu had similar visual outcomes as patients receiving own label of aflibercept throughout 1 year.
Very importantly, in that study, we show that patients that received Duravyu up to 6 months, two-thirds of the patients did not require any anti-VGF. Based on the results from the DAVIO 2 wet AMD study, we initiated our phase 3 programs, LUGANO and LUCIA. Those studies are now fully enrolled and we expect results in mid-summer of 2026.
Now turning back to DME, our phase 2 study, VERONA trial, we showed that patients that were dose with Duravyu early on in this study had better visual outcomes and see a reduction compared to the aflibercept group. Also, this highlights of our recent findings that Duravyu blocks VEGF receptor, PDGF, and also JAK1. Based on the strong results from the Phase 2 VERONA trial, in addition to our research findings, we are now initiating our phase 3 program, COMO and CAPRI, that are expected to enroll the first patients in Q1 of next year.
This is an exciting times for EyePoint as we roll out our 2 phase 3 programs in wet AMD and DME; 2027 is going to be a very important year for us.
Related Content
